株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

自己免疫溶血性貧血 (AIHA) の主要8ヶ国市場の予測

Epiomic Epidemiology Series: Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026

発行 Black Swan Analysis 商品コード 363599
出版日 ページ情報 英文 48 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.78円で換算しております。
Back to Top
自己免疫溶血性貧血 (AIHA) の主要8ヶ国市場の予測 Epiomic Epidemiology Series: Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026
出版日: 2016年07月01日 ページ情報: 英文 48 Pages
概要

当レポートでは、世界の主要8ヶ国 (米国・フランス・ドイツ・イタリア・スペイン・英国・ブラジル・日本) における自己免疫溶血性貧血 (AIHA) の現在の患者数 (性別、年齢コホート別) について調査分析し、現在の有病率のほか、疾患の概要、危険因子、疾患の診断と予後、主な症状や合併症など、体系的な情報を提供しています。

イントロダクション

病因

危険因子と予防

疾患の診断

変異:地域/民族別

疾患予後と臨床経過

AIHAの臨床管理

  • AIHAの輸血療法

疾患に関連する主な合併症/特徴

患者数を定量化する手法

自己免疫溶血性貧血 (AIHA) の最大有病者数

自己免疫溶血性貧血 (AIHA) 患者の亜型

  • 温式己免疫溶血性貧血 (AIHA) 患者
  • 冷式己免疫溶血性貧血 (AIHA) 患者
  • 混合式己免疫溶血性貧血 (AIHA) 患者

己免疫溶血性貧血 (AIHA) の市場予測

  • 温式・混合式AIHAにおける第一の治療選択肢
  • 温式・混合式AIHAにおける第二の治療選択肢
  • 冷式AIHAにおける第一の治療選択肢
  • 冷式AIHAにおける第二の治療選択肢
  • AIHAにおける輸血の要件

予測の調査手法 図表

略語

関連出版

患者ベースのオンラインデータベース

患者ベースの製品

価格のオンラインデータ・プラットフォーム

参考文献

付録

図表

目次
Product Code: AIHA0010716

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Autoimmune Haemolytic Anaemia (AIHA) in 8 Major Markets

Autoimmune haemolytic anaemia (AIHA) is an immune disorder caused by auto-antibodies against unmodified autologous red blood cells and can range in presentation from a mild illness to a rapidly fatal severe condition.

This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AIHA's have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AIHA include:

  • Lymphoproliferative conditions:
    • CLL
    • HL
    • NHL
  • Myeloproliferative conditions:
    • Multiple myeloma
    • Myelofibrosis
    • MGUS
  • Autoimmune conditions:
    • RA
    • SLE
    • Polyarteritis nodosa
  • Infections:
    • Pneumonia & Tuberculosis
    • Syphilis
    • Epstein-Barr
    • Chronic active hepatitis
    • Mononucleosis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global AIHA's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of AIHA and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on AIHA's incident population.
  • Identify sub-populations within AIHA which require treatment.
  • Gain an understanding of the specific markets that have the largest number of AIHA patients.

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Clinical Management of AIHA
    • Transfusion therapy in AIHA
  • Key Co-morbid Conditions/Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Incidence for AIHA
  • Subtypes of AIHA patients
    • Warm AIHA patients
    • Cold AIHA patients
    • Mixed-type AIHA patients
  • Market Forecast for AIHA
    • 1st Line Treatment Options within Warm & Mixed-type AIHA
    • 2nd Line Treatment Options within Warm & Mixed-type AIHA
    • 1st Line Treatment Options within Cold AIHA
    • 2nd Line Treatment Options within Cold AIHA
    • Requirement for Blood Transfusions within AIHA
  • Methodology for Forecast Figures
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • Drugs implicated in development of AIHA
  • Tests for AIHA and expected findings in haemolysis
  • Classification of AIHA
  • Treatment options for warm AIHA
  • Treatment options for cold AIHA
  • Incidence of AIHA, total (000s)
  • Incidence of AIHA, males (000s)
  • Incidence of AIHA, females (000s)
  • Incident AIHA by main sub-type, total (000s)
  • Incident Warm AIHA by cause, total (000s)
  • Warm Secondary AIHA by main aetiology, total (000s)
  • Incident Cold AIHA by main type, total (000s)
  • Incident CAS AIHA by cause, total (000s)
  • CAS Secondary AIHA by main aetiology, total (000s)
  • Incident Mixed-type AIHA by cause, total (000s)
  • Mixed-type Secondary AIHA by main aetiology, total (000s)
  • Prednisolone estimated forecast 1st line, Revenue (£000s)
  • Rituximab estimated forecast 2nd line, Revenue (£000s)
  • Splenectomy estimated forecast 2nd line, Patients (000s)
  • Rituximab estimated forecast 1st line, Revenue (£000s)
  • Rituximab estimated forecast 2nd line, Revenue (£000s)
  • Transfusion estimated forecast, Patients (000s)
  • Abbreviations and Acronyms used in the report
  • USA Incidence of AIHA by 5-yr age cohort, males (000s)
  • USA Incidence of AIHA by 5-yr age cohort, females (000s)
  • France Incidence of AIHA by 5-yr age cohort, males (000s)
  • France Incidence of AIHA by 5-yr age cohort, females (000s)
  • Germany Incidence of AIHA by 5-yr age cohort, males (000s)
  • Germany Incidence of AIHA by 5-yr age cohort, females (000s)
  • Italy Incidence of AIHA by 5-yr age cohort, males (000s)
  • Italy Incidence of AIHA by 5-yr age cohort, females (000s)
  • Spain Incidence of AIHA by 5-yr age cohort, males (000s)
  • Spain Incidence of AIHA by 5-yr age cohort, females (000s)
  • UK Incidence of AIHA by 5-yr age cohort, males (000s)
  • UK Incidence of AIHA by 5-yr age cohort, females (000s)
  • Brazil Incidence of AIHA by 5-yr age cohort, males (000s)
  • Brazil Incidence of AIHA by 5-yr age cohort, females (000s)
  • Japan Incidence of AIHA by 5-yr age cohort, males (000s)
  • Japan Incidence of AIHA by 5-yr age cohort, females (000s)
Back to Top